All Bausch Health articles
-
News briefs
Bausch + Lomb sales of contact lenses slow down in Q2
Bausch + Lomb has reported that its sales of contact lenses in the second quarter of this year inched up by one percent year on year, totalling $215 million. At constant exchange rates, they were up by four percent versus Q2 2022, slowing down from a double-digit growth pace in ...
-
News briefs
Papa to step down as Bausch+Lomb CEO
Bausch + Lomb has announced that Joseph C. Papa had stepped down from his position of chairman of the company’s board of directors and that it was searching for a new CEO to replace him in his executive role. Until a successor is appointed, Papa will remain as CEO and ...
-
News briefs
B+L expands its board
Bausch + Lomb (B+L) has expanded its board of directors by two seats and filled them with Brett Icahn and Gary Hu, both from Carl C. Icahn and affiliates (Icahn Group). B+L has entered into an amended and restated Director Appointment and Nomination Agreement with Icahn Group, after the distribution ...
-
ArticleBausch + Lomb sees 5% organic sales growth in Q1 as IPO wraps up
Bausch Health sold 35 million common Bausch + Lomb shares, or a 10.0 percent stake, at a price of $18.00 per share, in an initial public offering yielding gross proceeds of $630 million and valuing its subsidiary at about $6,300 million. Joseph Papa, chairman of Bausch Health and CEO of ...
-
News briefs
Bausch + Lomb to be spun off in IPO
Bausch Health Companies is spinning off Bausch + Lomb Corporation. The announcement came on April 28 that Bausch + Lomb would be making an initial public offering of 35.0 million common shares on the New York Stock Exchange (NYSE) and the Toronto Stock Exchange (“TSX”), under the ticker symbol BLCO ...
-
News briefs
Bausch + Lomb to contract $2.7 bn loan before IPO
Bausch Heatlh has announced that its subsidiary Bausch + Lomb was looking into securing a new credit agreement ahead of its Initial Public Offering (IPO), scheduled to take place in the course of this year. The company is seeking to contract a $2.5 billion term B loan and an additional ...
-
ArticleEyewear industry stock prices down 13% in Q1
The first quarter of 2022 was the worst quarter for global equity markets since the first quarter of 2020 when the Covid-19 pandemic started spreading worldwide, leading to travel restrictions and lockdowns and prompting stock markets to collapse in March. Since the start of this year, the U.S. equity market ...
-
ArticleBausch Health files for IPO of its eyecare business
In its quest to split into three publicly traded companies, Bausch Health has filed to make an initial public offering of common shares in the U.S. and most of Canada for its wholly owned subsidiary Bausch + Lomb Corporation. Specifically, it has filed a Registration Statement with the U.S. Securities ...
-
ArticleTop 5 eyewear companies’ stock prices up 4.6 % in Q4
We are updating here our quarterly chart on the evolution of stock prices for the public companies in the eyewear market, including manufacturers, distributors or retailers of contact lenses, prescription lenses, eyeglasses and sunglasses. We are also publishing a ranking of these 22 companies based on their stock market value. ...
-
ArticleEyewear industry stock prices up 3.5% in Q3
We are publishing here our quarterly update on the evolution in stock prices of public companies operating in our core eyewear market, including manufacturers, distributors or retailers of contact lenses, prescription lenses, eyeglasses and sunglasses. As shown in the chart below, the non-weighted average growth for the 22 companies included ...
-
News briefs
Bausch + Lomb Q2 sales up 33%
Bausch Health reported a year-on-year increase of 38 percent to $934 million in quarterly revenues for its Bausch + Lomb (B + L) unit. In constant currencies, B + L Q2 sales grew by 33 percent from the same period in 2020. The unit’s revenue growth was driven ...
-
ArticleBausch gears up to spin off B+L
As part of its quarterly results’ announcements, Bausch Health said that it was accelerating the preparations for the spin-off of its Bausch + Lomb business. Having just completed its financial segmentation of the unit, the company said it expects to be ready for the operation in Q3 2021. ...
-
News briefs
Bausch Health might sell Bausch+Lomb, rather than spin it off
Quoting sources close to the matter, Bloomberg News reported last week that Bausch Health was currently exploring the possibility of a sale of its Bausch+Lomb ’s eye care business unit, instead of the initially planned spin-off. Before being renamed as Bausch Health, Valeant Pharmaceuticals International had acquired ...
-
News briefs
Bausch Health pursues debt reduction
Bausch Health announced on April 7 that it will reduce its debt by another $100 million in May through the redemption of outstanding senior secured notes, using cash generated from operations. The Canadian group had already redeemed a total of $200 million through a similar operation in March. Last ...
-
ArticleEyewear industry stock prices up 10% in Q1
Following the publication for the first time of our industry stock market capitalization at the start of the year, we are providing here a quarterly update for the evolution of the stock price of 19 stock listed companies operating in our core market, showing its evolution between Jan. 1 and ...
-
News briefs
Bausch Health appoints new CFO, prepares B+L spin off
The Canadian healthcare company Bausch Health announced the appointment of Paul Herendeen , its chief financial officer since 2016, to the newly created position of advisor to the chairman and CEO of the company, starting June 1. Herendeen’s CFO responsibilities will be transferred to Sam Eldessouky , who joined ...
-
Article
Bausch Health expands board after deal with activist shareholder
The Canadian healthcare company Bausch Health will expand its board of directors to add two representatives of the activist investor Carl Icahn. With the two new appointments, the board will have 13 directors. Under the agreement, Brett Icahn and Steven Miller will be appointed to the ...
-
News briefs
Activist investor builds up stake in Bausch Health
The activist investor Carl Icahn disclosed that he has bought 27.8 million shares in Bausch Health , becoming the largest shareholder with a 7.83 percent stake. Following the news, Bausch Health issued a statement saying that its board and management “welcome open communication with our shareholders and constructive ...
-
ArticleEyewear industry stocks grew by 6% in 2020
We are publishing here for the first time our ranking of the main stock-listed eyewear industry companies, based on their stock market capitalization in euros at the end of 2020. The corresponding table also shows the change in market value from the previous year, both in local currency and euros. ...
-
News briefs
Bausch Health repaid $900m in debt in 2020
Bausch Health repaid some $900 million in debt in 2020 from cash on hand and cash generation. The company has no debt maturities or mandatory amortization payments until 2024. In the fourth quarter, the company repaid about $480 million in debt, the last payment being made on Dec. ...
